Rofecoxib: first COX-2 inhibitor for UK

摘要

Merck Sharp & Dohme's nonsteroidal anti-in-flammatory drug (NSAID) rofecoxib hs been approved in the UK for the symptomatic treatment of osteoarthritis (OA). The drug is now on the market, as Vioxx (see p860).